Loc108167440 suppressed myeloma cell growth by P53-mediated apoptosis

References

• Franqui-Machin R, Hao M, Bai H, et al. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018;128:2877–2893.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
   PubMed Web of Science ®Google Scholar
• Mahtouk K, Cremer FW, Reme T, et al. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene. 2006;25:7180–7191.
   PubMed Web of Science ®Google Scholar
• Kumar A, Loughran T, Alsina M, et al. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol. 2003;4:293–304.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, van de Donk N, Zweegman S, et al. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78:19–37.
   PubMed Web of Science ®Google Scholar
• Anderson KC. The 39th David A. Karnofsky lecture: bench-tobedside translation of targeted therapies in multiple myeloma. Jco. 2012;30:445–452.
   PubMed Web of Science ®Google Scholar
• Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336:1657–1664.
   PubMed Web of Science ®Google Scholar
• Shapiro VS, Mollenauer MN, Weiss A. Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression. Blood. 2001;98:187–193.
   PubMed Web of Science ®Google Scholar
• Flores-Montero J, de Tute R, Paiva B, et al. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry. 2016;90:61–72.
   PubMedGoogle Scholar
• Roy P, Sarkar UA, Basak S. The NF-kB activating pathways in multiple myeloma. Biomedicine. 2018;6:59.
   Google Scholar
• Gonzalez D, van der Burg M, Garcia-Sanz R, et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood. 2007;110:3112–3121.
   PubMed Web of Science ®Google Scholar
• Benson DM, Jr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116:2286–2294.
   PubMed Web of Science ®Google Scholar
• Hallett WH, Jing W, Drobyski WR, et al. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant. 2011;17:1133–1145.
   PubMed Web of Science ®Google Scholar
• Ray A, Das DS, Song Y, et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015;29:1441–1444.
   PubMed Web of Science ®Google Scholar
• Tremblay-LeMay R, Rastgoo N, Chang H. Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. J Hematol Oncol. 2018;11:46.
   PubMed Web of Science ®Google Scholar
• Tamura H, Ishibashi M, Yamashita T, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2013;27:464–472.
   PubMed Web of Science ®Google Scholar
• Gorgun G, Samur MK, Cowens KB, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21:4607–4618.
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840–1848.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7:311–321.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270:95–112.
   PubMed Web of Science ®Google Scholar
• Paiva B, Azpilikueta A, Puig N, et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia. 2015;29:2110–2113.
   PubMed Web of Science ®Google Scholar
• Xu R, Fang Y, Hou C, et al. BC094916 suppressed SP 2/0 xenograft tumor by down-regulating Creb1 and Bcl2 transcription. Cancer Cell Int. 2018;18:138.
   PubMed Web of Science ®Google Scholar
• Zhu G, Liu X, Fang Y, et al. Increased mTOR cancels out the effect of reduced Xbp-1 on antibody secretion in IL-1α-deficient B cells . Cell Immunol. 2018;328:9–17.
   PubMed Web of Science ®Google Scholar
• Ozcan E, Garibyan L, Lee JJ, et al. Transmembrane activator, calcium modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells. J Allergy Clin Immunol. 2009;123:1277–1286.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Y, Wang Z, et al. Metabotropic glutamate receptor 3 is involved in B-cell-related tumor apoptosis. Int J Oncol. 2016;49:1469–1478.
   PubMed Web of Science ®Google Scholar
• Ma N, Liu X, Xing C, et al. Ligation of metabotropic glutamate receptor 3 (Grm3) ameliorates lupus-like disease by reducing B cells. Clin Immunol. 2015;160:142–154.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101–119.
   PubMed Web of Science ®Google Scholar
• Rossi M, Botta C, Arbitrio M, et al. Mouse models of multiple myeloma: technologic platforms and perspectives. Oncotarget. 2018;9:20119–20133.
   PubMedGoogle Scholar
• Ria R, Reale A, Vacca A. Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol. 2014;4:73–90.
   PubMedGoogle Scholar
• Pichiorri F, Suh SS, Rocci A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010;18:367–381.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013;19:3337–3344.
   PubMed Web of Science ®Google Scholar
• Brown RD, Pope B, Yuen E, et al. The expression of T cell related costimulatory molecules in multiple myeloma. Leuk Lymphoma. 1998;31:379–384.
   PubMed Web of Science ®Google Scholar
• Racanelli V, Leone P, Frassanito MA, et al. Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood. 2010;115:1185–1193.
   PubMed Web of Science ®Google Scholar
• Klippel ZK, Chou J, Towlerton AM, et al. Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther. 2014;21:337–342.
   PubMed Web of Science ®Google Scholar